argenx's $0.26 Billion Volume Ranks 386th in Market Activity as Analysts Maintain Strong Buy Stance

On September 9, 2025, , ranking 386th in market activity. .

Analyst activity remained supportive, . HC Wainwright reiterated its Buy recommendation earlier in the month. The stock’s average analyst rating stands at Strong Buy, , .

Recent corporate developments included Health Canada’s authorization of Vyvgart for generalized myasthenia gravis, expanding the drug’s commercial reach. Institutional activity also drew attention, , while SG Americas Securities LLC and Armistice Capital LLC made purchases. Additionally, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval for subcutaneous efgartigimod, a key product in argenx’s pipeline.

To run this back-test reproducibly, key implementation details must be pinned down: market universe (e.g., S&P 1500 vs. broader universe), volume metric (share-volume vs. dollar-volume), portfolio weighting (equal-weight vs. volume-proportional), (rebalance timing), and frictional cost assumptions (bid-ask spreads, commissions). , 2022.